

Sangamo Biosciences to Webcast Presentation at the Wall Street Analyst Forum 51st NYC Analyst Conference

RICHMOND, Calif., February 25 /PRNewswire-FirstCall/ --Sangamo BioSciences, Inc. (Nasdaq: SGMO) today announced that Edward Lanphier, the company's president and chief executive officer, will present a company update at the Wall Street Analyst Forum, 51st NYC Analyst Conference on March 2, 2004 at 11:00 am (ET) in New York City.

A live webcast of this presentation will be available via a link on the Sangamo BioSciences website in the Investor Relations section under "Company Overview". A replay of the presentation will be available on the Sangamo website for two weeks after the event.

About Sangamo

Sangamo Biosciences, Inc is focused on the research and development of novel transcription factors for therapeutic gene regulation and repair. The company's most advanced therapeutic development program involves the use of transcription factors for the treatment of peripheral artery disease. Other therapeutic development programs are focused on ischemic heart disease, cancer, neuropathic pain, and monogenic diseases. Sangamo's core competencies enable the engineering of a class of transcription factors known as zinc finger DNA binding proteins (ZFPs). By engineering ZFPs that recognize a specific DNA sequence Sangamo has created ZFP transcription factors (ZFP TFs) that can control gene expression and consequently, cell function. Sangamo is also developing sequence-specific ZFP nucleases (ZFNs) for therapeutic gene correction as a treatment and possible cure for a variety of monogenic diseases such as severe combined immunodeficiency and sickle cell anemia. For more information about Sangamo, visit the company's web site at www.sangamo.com or www.expressinglife.com.

This press release may contain forward-looking statements based on Sangamo's current expectations. These forward-looking statements include, without limitation, references to the research and development of novel ZFP TFs, ZFNs and therapeutic applications of Sangamo's ZFP technology platform. Actual results may differ materially from these forward-looking statements due to a number of factors, including technological challenges, Sangamo's ability to develop commercially viable products and technological developments by our competitors. See the company's SEC filings, and in particular, the risk factors described in the company's Annual Report on Form 10-K and its most recent 10-Q. Sangamo assumes no obligation to update the forward-looking information contained in this press release.

Contact:

Elizabeth Wolffe, Ph.D. 510-970-6000, x271 Manager, Corporate Communications ewolffe@sangamo.com

Burns McClellan, Inc. Tricia Morsch (media) 212-213-0006 Michelle Levine (investors) 415-352-6262